Open Access
CC BY 4.0 · World J Nucl Med
DOI: 10.1055/s-0045-1809342
Review Article

Targeted Alpha Radiopharmaceutical Therapy and Key Considerations for Nuclear Medicine Technologists

1   Department of Nuclear Medicine Technology, GateWay Community College, Phoenix, Arizona, United States
,
Daryn Groves
2   Division of Nuclear Medicine, Department of Radiology, Mayo Clinic, Scottsdale, Arizona, United States
› Institutsangaben
Preview

Abstract

The use of radionuclides for targeted radiopharmaceutical therapy (RPT) is a rapidly evolving field in nuclear medicine and oncology. With the integration of imaging and therapy, therapeutic nuclear medicine has made remarkable progress in recent years. One particularly promising area of research is the use of α-emitting radionuclides, which possess unique physical properties that provide notable advantages, including the ability to target single tumor cells with high precision. Although the only targeted α therapy (TAT) currently approved by the United States Food and Drug Administration is 223Ra-dichloride for the treatment of castration-resistant prostate cancer with skeletal metastases, a search on clinicaltrials.gov yields a significant number of early- and late-stage clinical trials utilizing 223-Ra, 225-Ac, 211-At, 212-Pb, and 227-Th are in progress, indicating that more TATs are on the horizon. As the prevalence of use for TAT increases, it is important to consider the logistics of TAT administration and the requirements for radiation safety and patient discharge. This review aims to provide a comprehensive overview of the advancements, relevant clinical trials, and logistical considerations associated with targeted α RPT in oncology.

Authors' Contributions

J.B. was the primary author of the manuscript. She was also responsible for resource gathering and review, clinical trials review, authorship of four-fifths tables, manuscript review, and manuscript revisions. D.G. was responsible for secondary authorship of the manuscript, manuscript review, and authorship of the radiation safety/discharge instructions table and other clinical recommendations. J.B. and D.G. have read and approved the manuscript. Both authors believe the manuscript represents honest work.




Publikationsverlauf

Artikel online veröffentlicht:
03. Juni 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India